Latest / Conversations with CEI / CEI…we got you! Evolving with the Science
Transcript
- 0:02Welcome to the Clinical Education Initiative podcast, Conversations with CEI,
- 0:07where we feature conversations with clinical experts, their experience and insights
- 0:13on current health issues in the areas of HIV,
- 0:17Primary Care and Prevention, Sexual Health,
- 0:21Hepatitis C, and Drug User Health.
- 0:23Today, we are here in Rochester, New York, live with CEI, the New York State
- 0:28Clinical Education Initiative.
- 0:31And we're speaking with leading physicians who have been on the front lines
- 0:34of translating rapidly evolving science into practice and education for all of New York.
- 0:41From our roots in CEI of advocating for clinical education in the very early
- 0:45days of HIV treatment to now our modern approaches in training on the syndemics,
- 0:50such as drug use of health,
- 0:52harm reduction, hep C, STIs, we're exploring how the science around these syndemics
- 0:57has transformed and what that means for continuing education around the state.
- 1:02Let me take a moment to introduce our incredible panel of experts today.
- 1:07We have Dr. Tony Urbina, who is an infectious disease physician and the medical
- 1:11director for the Mount Sinai Institute for Advanced Medicine in New York City
- 1:16and specializes in HIV care prevention and treatment.
- 1:19Dr. Daniela DiMarco is an infectious disease physician and has a master's in public health.
- 1:24She is currently an assistant professor of medicine at the University of Rochester,
- 1:30specializing in HIV, sexual health, and STIs.
- 1:34Dr. Linda Wang is a general internist and an addiction medicine specialist and
- 1:39serves as the medical director for the Hepatitis C and Drug User Health Center
- 1:43of Excellence at Mount Sinai Medical Center in New York City.
- 1:47Dr. Stephen Fine is an infectious disease physician at the University of Rochester
- 1:52and has spent years as the Hep-C medical director at a local federally qualified health clinic. Dr.
- 1:59Timothy Dye leads our CEI Resource Center.
- 2:04He is a medical anthropologist and social epidemiologist who specializes in
- 2:09biomedical informatics and data science, particularly at the intersection of science and health.
- 2:16So let's start with talking about the science. Clinical guidelines,
- 2:20really, in each of your areas of expertise has changed pretty dramatically,
- 2:23and sometimes even overnight.
- 2:26So I'd just like to hear about you, about the evolution of both the science and education.
- 2:30First, I'll start with you, Dr. Urbina. So, in terms of HIV,
- 2:35how have really the landmark shifts of U-Equals-U and really the new long-acting
- 2:42injectable HIV treatments really changed the landscape for your patients and
- 2:47also for your colleagues and
- 2:49clinicians and how we educate clinicians throughout the state? Yeah, sure.
- 2:54Thank you, Brianna. So I think U equals U has been such a pivotal kind of phenomenon,
- 3:00just helping our patients reduce stigma.
- 3:03I think it's really in line with our rapid starts and getting patients living
- 3:07with HIV to undetectable, just unequivocally undetectable.
- 3:12You cannot simply transmit HIV infection. So I think that's really galvanized
- 3:16just our HIV treatment and just our rapid start initiatives.
- 3:19With regard to novel agents, I'm most excited about these long-acting injectables,
- 3:25in particular patients that are viremic.
- 3:29So we know that there are indications really as a switch for patients that are
- 3:33suppressed, but now there's been published reports about patients that have
- 3:38viremia and start them on these long-actings, and then they can get to U equals U.
- 3:43In addition to that, I think there's newer all agents. I think the big kind
- 3:48of issue with HIV is patients are living with HIV in their 70s,
- 3:5180s, and 90s and beyond. I think my oldest patients find them.
- 3:54So I think with these newer agents, we're starting to see drugs that maybe have
- 3:57less toxicity, less issues with weight gain, metabolic disorders.
- 4:02So I think these two drug combinations that are going to be free of certain
- 4:06antivirals are really interesting.
- 4:09And then lastly, I think just new ways to dose the medication.
- 4:12So not so much daily, but we have weekly and maybe even monthly options that
- 4:17would be available for patients.
- 4:19All of this really involves, I think, CEI's input in terms of training physicians,
- 4:24not just about the science, but about how to implement.
- 4:27Yeah, absolutely. It sounds like really the landscape can really empower our patients.
- 4:34And hopefully we're educating our clinicians really to do that.
- 4:37Stigmatizing U equals U is so important, I think, empowering your patients.
- 4:41But then just the flexibility in order to have a patient-centered approach,
- 4:46almost like a menu of options from what works for these patients,
- 4:50I think is going to be so exciting for the individual relationship between the
- 4:53patient and the clinician and how they talk about that.
- 4:57So I think it'll be interesting if really how that comes out and CEI will take
- 5:00a lead role or kind of leading that really wonderful patients at their therapeutic relationship.
- 5:07I couldn't agree with you more. Yeah. And just a little bit more,
- 5:10I know there's currently an injectable PrEP, so HIV prevention.
- 5:15And soon there's going to be an FDA approved once every six month injectable
- 5:20PrEP formulation, lenacapavir.
- 5:23I'm just curious your thoughts about, one, how this could change the landscape
- 5:26and the epidemic, and also, you know, how we can help clinicians implement this for their patients.
- 5:33Yeah, yeah. I think just like you mentioned, I think the more options we have
- 5:38for patients, the more we can reach, like, populations that may be more impacted by HIV.
- 5:45Maybe that are not as trusting of, like, medical establishments and things like
- 5:49that by providing different routes.
- 5:52So I'm very excited about lenacapavir.
- 5:55It's going to be two subcutaneous injections every six months.
- 6:00When they first start, I'm going to get an injection plus two tablets.
- 6:05Now on the second day, two tablets.
- 6:06And then their next injection is until six months. So I'm thinking that that
- 6:10might appeal to like women,
- 6:13maybe people that use drugs, just different types of populations where maybe
- 6:18an alternative to having to take something every day is not as attractive.
- 6:23So I'm really excited that I think with these novel technologies that we may
- 6:28be able to target different groups and then really get to our goal of like ending
- 6:33the epidemic. Yeah, totally agree.
- 6:35And I think what's important is when we have something that's like every six
- 6:39months an injectable, potentially clinicians can be thinking about how they can.
- 6:45Like partner with community-based organizations where traditional populations have a lot harder time.
- 6:51It's very hard to get into our healthcare system, right?
- 6:54But populations that maybe are accessing, you know, things outside the healthcare
- 6:58system that are willing to partner.
- 7:00You need to sort of take those very novel interventions and bring them sort
- 7:04of outside sometimes the traditional healthcare system. So, yeah, I agree with that. Yeah.
- 7:08And I also think CEI has helped because currently we have this long-acting intramuscular
- 7:14PrEP agent, yeah, long-acting Cabotegravir.
- 7:16I think CEI is really helpful in helping institutions and clinics and individual
- 7:22providers kind of implement it. So I think that's the biggest challenge.
- 7:26Like the science is there and these medications work, but how long do you access the medications?
- 7:31How long do you get it authorized? All of those steps and insurances in our
- 7:35kind of complicated health insurance system, I think it helps to have kind of guidance.
- 7:40About how one can roll it out successfully.
- 7:43Yeah, absolutely. So we will look forward to CEI doing, you know,
- 7:47helping that as the new medications get approved.
- 7:50Thank you. Do you think the long-acting Lenacapavir will be available in primary
- 7:56care offices or outside of the spectrum?
- 7:59Right, right. I think that's a super good question.
- 8:03I think there needs to be an infrastructure in place to kind of implement that.
- 8:09I think it relies heavily on nursing, you know, just to perform these injections.
- 8:15Not that clinicians couldn't do it, but so I think infrastructure is really important.
- 8:21I do think that the medication will be able to be accessed via these pharmacy benefits.
- 8:25So there could be alternatives for accessing the medication,
- 8:29but I do think that we need to have a robust injection practice.
- 8:34In order to do it successfully. So maybe we'll have designated kind of centers
- 8:39of excellence for this, but I'm hopeful that more people kind of buy in and want to do it.
- 8:43Yeah. And I think, you know, what's important is making sure we're educating
- 8:47people about the science, but then also making sure we also have trainings about
- 8:52exactly what you're saying.
- 8:53How do you implement this in things like primary care? How do you make the slow barrier, etc.
- 8:58So moving on to kind of STI prevention, I wanted to ask Dr. DiMarco a question.
- 9:06So we are in an era where we finally have one of the first biomedical STI prevention,
- 9:12meaning a medication to prevent sexually transmitted infections called DOXY PEP.
- 9:17As the lead author and actually of the New York State DOXY PEP guidelines,
- 9:21we've really been on the forefront of shaping that evolution of STI prevention.
- 9:25So, like, how do you think this strategy has been incorporated by physicians?
- 9:31Are they taking it up? How do you think the community of patients have responded
- 9:35to this really new innovative approach that we haven't had for forever?
- 9:39Yeah, that's a great question. I think we're seeing a little bit of what we
- 9:43saw when oral PrEP was first rolled out several years ago, where there is...
- 9:49Quite a bit of consumer or patient awareness, and people are looking for the
- 9:54medication, they're looking for that prevention option.
- 9:57It's not going to solve, you know, the epidemic of STIs in New York State or nationally,
- 10:04but it's absolutely something that has been shown in several trials to be highly
- 10:08effective in some populations that have elevated potential for STI exposure.
- 10:13It's a great option for some folks.
- 10:15You know, we see hesitancy and, you know, how do we approach out with clinicians.
- 10:21I think clinicians look for data. So they really want to see science guiding practice.
- 10:25So what's the data in terms of patient or consumer needs, wants,
- 10:29acceptability? That really looks favorable.
- 10:32What's the science? You know, what's been published in terms of not just efficacy, but effectiveness?
- 10:37And so we've seen some pretty favorable publications coming out from that respect as well.
- 10:42As we get that information out there and as we give providers tools and training
- 10:47to sort of expand or, you know, just increase how they're doing this in their
- 10:52practice, you know, we're seeing uptake expand as well.
- 10:57And so we have a couple of quick reference tools that we put out there.
- 11:01New York State guidelines came out over six months before CDC guidelines.
- 11:05So both that providers out there in New York are, you know, using the guidelines
- 11:11to help them implement this into their practice.
- 11:14A lot of folks are just looking, not just in primary care, but even in STI clinics,
- 11:21in various places, how can you incorporate this component of the sexual health toolbox?
- 11:27It really also starts with just taking my sexual history as far as routine visits.
- 11:31And so you maybe won't know it's an option for your patient unless
- 11:35you launch in with just you know some basic questions so
- 11:38I think there's a lot of opportunities to expand implementation
- 11:41we have sand updates the the patient
- 11:45awareness is out there it's not as high as it has
- 11:48been for PrEP HIV PrEP and so there's still quite a bit of work to do on the
- 11:52patient education side as well as the prevention side yeah absolutely and I
- 11:57like what you said I think you know CEI how taken obviously we have done you
- 12:02know historically really you know cared about STI prevention and treatment.
- 12:06But I think what's been really nice is that you all have also taken a pretty
- 12:10sexual health approach to educating clinicians.
- 12:15I love that you have how to take a sexual history as part of the CEI platforms.
- 12:23And I think the more that we bring all physicians to consider sexual health
- 12:28as part of regular health, the more likely we are going to be able to implement and
- 12:32use these really wonderful biomedical interventions.
- 12:35So I'm just, you know, how has the perceived then sort of really trying to get
- 12:41clinicians to open that conversation up and are people interested in this topic? Yeah, absolutely.
- 12:46Clinicians out there want to do what's best for their patients and they are
- 12:51really constrained by time.
- 12:53And so, you know, everybody's doing the best they can.
- 12:56And when you think about, oh, you know, as a sexual history,
- 13:00you might have to spend 15 minutes talking about all these different things.
- 13:03And what about the privacy of it?
- 13:04And there's a lot of things that could pull you back a little.
- 13:09But I think clinicians will find as they start to do it that patients do actually
- 13:13want to talk about things. It does take a little bit of trust building.
- 13:17So maybe it's just one question at the first visit. And as you build that relationship,
- 13:21you start adding a little bit more.
- 13:23But it really is meant to be a conversation and not sort of several questions
- 13:28in a row without any give and take.
- 13:30And so as you open that conversation, you get to know more. And it's not just about STIs.
- 13:35Maybe it's also about pregnancy planning, be it prevention or fertility questions.
- 13:40It's about partners. It's about safety in terms of, you know,
- 13:44maybe you do have to ask some folks about trafficking and things like that.
- 13:48And, you know, we also ask about sexual function and pleasure.
- 13:52There's just a lot that goes into it. But you, you know, don't necessarily need
- 13:56to feel like you're asking that all at once and that, you know,
- 13:59take it in stride as you get the signs from a patient through the conversation.
- 14:04Yeah, I think that's important. Just, I always laugh, like, making,
- 14:08are you having sex is a vital sign, you know?
- 14:12Daniela, I often get asked this question, so I'll be curious to see your thoughts,
- 14:16just for Doxy PEP vaginal exposure.
- 14:20How long do you counsel your patients or other clinicians about that?
- 14:24Yeah, that's a tough one because the data that we have so far hasn't been favorable in terms of efficacy.
- 14:31There was a trial that was conducted in Kenya with cisgender women who were
- 14:35on HIV-PrEP, and it didn't show that it's an STI reduction, but there appear
- 14:40to have been some experience issues in a small sample there.
- 14:44But there's a couple other studies that are ongoing.
- 14:47Way there's one pharmacy, pharmoconetic study, but the other,
- 14:52you know, animal model study in the cats with like a doxycycine insert looked
- 14:57favorable, but the other sort of human models that they've looked at so far.
- 15:02There's sort of mixed results.
- 15:05And so I don't know what we're going to end up seeing. And we don't have sort
- 15:08of a really great planned randomized trial for this.
- 15:11And, you know, folks assigned female at birth, you know, they deserve great
- 15:15data and great trials soon.
- 15:17But I think there's an opportunity, depending on the person's potential for
- 15:21STI exposure, that you might sort of counsel them through, you know,
- 15:26this is what we know, and it's not a lot.
- 15:28And this is what we know about your chance of getting an STI over the next six months.
- 15:33So let's try to balance those individually and see if you can come up with the answer.
- 15:40I like that. So I have a shared decision, right, based on the best of them. Yeah.
- 15:45Thanks. And keeping them the care. So, you know, what's interesting is a lot
- 15:49of what we're talking about, we don't traditionally think of as harm reduction, right?
- 15:53But we're really talking about how to reduce harm when people are engaging in sexual activity.
- 15:59And, you know, but traditionally, we often think of harm reduction in the context
- 16:03of drug user health. And so I'd like to really turn to Dr.
- 16:07Wang and ask you, you know, as the concept of harm reduction and specifically
- 16:12like harm reduction around drug use and substance use disorder has become almost
- 16:18becoming the medical standard,
- 16:20how does your framing of substance use disorder and stigma and care delivery
- 16:25in a primary care setting, how has that evolved?
- 16:27And how do you talk to clinicians about caring for patients who have multiple
- 16:33risks and how to reduce harm?
- 16:35Yeah, I think it's opened the door. And so like Tony was saying,
- 16:38now we have a menu of options and we have the ability to counsel people on many
- 16:43different pathways that we can take.
- 16:45Historically, I think we've only, you know, we've been trained that abstinence
- 16:51is sort of the gold standard way of dealing with a substance use disorder.
- 16:55And with harm reduction, I think it's really opened the doors to clinicians
- 17:00and patients and family members considering other options that may work best
- 17:05for that individual in front of them.
- 17:07Not everyone is going to want to pursue abstinence.
- 17:12And now we don't have to say, well, sorry, you know, we don't have any other options for you.
- 17:17We can say, okay, well, let's talk about all the other ways that we can keep you safe and healthy.
- 17:21And I think harm reduction really gets at that humanness of everything,
- 17:25of healthcare, that I think sometimes is missing when we focus so much on the biotherapeutics.
- 17:30And I think it's really important now more than ever for not just CEI,
- 17:34but all providers and all health agencies to really double down on the messaging
- 17:39that harm reduction is safe. It's effective.
- 17:43It has decades of evidence backed by science to show that it helps reduce things
- 17:48like HIV transmission, hepatitis C transmission.
- 17:51It reduces morbidity and mortality
- 17:53related to opioid overdose and other complications related to opioid use.
- 17:58And I, you know, I'm really fearful because we're in a landscape now where harm
- 18:03reduction is under attack nationally, regionally, and locally.
- 18:07From San Francisco to New York City, what we're seeing are legislations that
- 18:12do not protect harm reduction.
- 18:13We're seeing funding cuts across the board, which I think everyone in this room has experienced.
- 18:18And so I think because of harm reduction being under attack,
- 18:22I think we as an organization, we as providers in this healthcare system really
- 18:26need to double down on our messaging.
- 18:28We need to say, look, harm reduction saves lives.
- 18:32These are the facts and address the myths that go along with harm reduction,
- 18:36which have a lot to do with stigma, right? Stigma and lack of understanding and education.
- 18:41And we also need to be clear what providers need because the clinical infrastructure,
- 18:46as Tony was pointing out, doesn't necessarily exist the same way in many different settings.
- 18:52And so we may need to pivot and talk about harm reduction and harm reduction
- 18:56messaging in different ways and different practices so it better serves the
- 18:59need, not just the provider population, but also the patient population.
- 19:02Yeah, I totally agree. And I think what I like about CEI is there's the you
- 19:08know there's a lot of conversation on anti-stigma and actually giving losses
- 19:12and trainings on how to you know.
- 19:14Trauma-informed care, anti-stigma around many things, including Drug User Health.
- 19:19But I think we also have a lot of actually skill-based trainings on how to bring
- 19:23harm reduction into your clinical room with the patient.
- 19:28And what I think is also kind of like when we talk with all of us,
- 19:30it's also all about keeping the person in patient care, right?
- 19:34We know we can save lives if we're reducing harm.
- 19:38People gain trust with their clinicians. We have patient-centered approaches
- 19:42where the clinician and the patient are kind of, you know, having a conversation
- 19:46about what's best for them to one, stay alive and two, to stay alive healthier.
- 19:51So I think that's really great. And, you know, and I love that.
- 19:54But I haven't yet to keep going about that to keep our loved ones safe.
- 19:58I will say one of, one of, and also in the last decade, you know,
- 20:03we had a really effective treatment for opioid disorder. And obviously we are
- 20:07in an opioid epidemic and that is buprenorphine.
- 20:10And I think one of the things that was done federally was to reduce the DEA
- 20:15did take away the waiver in order to prescribe buprenorphine, right?
- 20:19So theoretically, we should be having a lot more prescribing. One,
- 20:22I'm curious if I think that the communities have picked up buprenorphine treatment
- 20:27in sort of outside of specialty care, meaning in primary care and other non-traditional
- 20:32sort of non-specialty care places or non-traditional healthcare their settings,
- 20:36and also how CEI and how training can sort of more effectively get people to
- 20:43also be treating, to be treating and discussing harm reduction sort of simultaneously.
- 20:48I'm aware of emerging data that do suggest that since the federal deregulation,
- 20:53the elimination of the X waiver, that there may be more prescribers,
- 20:57but I don't think we're seeing enough.
- 21:00And I don't think we're seeing enough prescribing from existing prescribers
- 21:04or even the new pool of prescribers.
- 21:06And I think eliminating the waiver was a necessary step, but it's only one part
- 21:10of a larger multi-pronged effort to sort of encourage provider uptake as with anything.
- 21:15Certainly it was a barrier and we're so happy the barrier is gone,
- 21:18but I think stigma remains in trend, lack of provider support remains a challenge.
- 21:24I love that Tony was talking about long-acting injectables because I do think
- 21:27one of the things we're trying to do with our center is really talk about rapid
- 21:31buprenorphine initiation via long-acting injector dopamine,
- 21:35which is available weekly and monthly formulations, and I think has a lot of benefits.
- 21:40You no longer have to go to the pharmacy on a monthly basis or biweekly basis.
- 21:45You don't have to deal with the highs and lows of the medication peaking and
- 21:49then dropping very quickly.
- 21:51So I think that's sort of the next move is thinking about what are the more
- 21:56innovative low-barrier models to treatment that we can teach more people about
- 22:00and also teach them how to implement in various clinical settings that may not
- 22:04have all resources.
- 22:05I agree to your question earlier, infrastructure is a huge issue and.
- 22:11Buying bill models may not be available for all the clinics,
- 22:14even though buying bill, I
- 22:15think, is a favorable and a better way of implementing these injectables.
- 22:19So you may have to use particularly seen competency benefits,
- 22:21but we need to be able to pivot easily to talk about how to do this implementation in various settings.
- 22:26And also, I think we probably need to hear more from the providers and collect
- 22:30more data. I don't know that I have a good sense in New York State.
- 22:34What does buprenorphine prescribing look like? We need to know who's prescribing,
- 22:39who's not prescribing, how is it happening, because I would love to expand it
- 22:43for all frontline provider settings, primary care, QHCs, you name it.
- 22:47Yeah, I was going to say, wouldn't it be great if somebody could get their sexual
- 22:52health care, their buprenorphine, their hep C treatment and their HIV PrEP all in the same place?
- 22:57And, you know, it makes sense and it's such a great idea.
- 23:01But in so few places and large purposes of how the funding streams are and the
- 23:05infrastructure, can you actually do all those things together? Yeah.
- 23:10And I think as we, you know, think about it, we really do need to take a patient-centered,
- 23:15syndemic approach and test and treat.
- 23:17And all of these settings are important. And speaking of test and treat, I'm going to talk to Dr.
- 23:21Fine about hepatitis C, which we are, you know, currently, really,
- 23:26we went through such a long, difficult regimens, right, in the early stage of hepatitis C.
- 23:31We really have, you know, one of the biggest scientific advancements of our
- 23:34time is that we have highly curative therapies, right, and under a decade for
- 23:39hep C, and a lot of ways, the test and treat model.
- 23:42So, you know, how did this really huge scientific shift change your urgency
- 23:46and optimism when delivering clinical education?
- 23:49And, you know, do you feel like that we've gotten there in terms of,
- 23:54I know, you know, we've done really well in New York compared to a lot of the
- 23:57state, but how have we gotten there in terms of test and treat,
- 24:00curing people, implementing this, and what can we do better?
- 24:05Yeah, those are really great and important questions.
- 24:09Since I have been treating hepatitis C, there's been such a dramatic shift in
- 24:15what we used to do for people who don't remember.
- 24:17If we required specialized patient education to teach them how to give themselves
- 24:23injections multiple times a week that basically made them feel like they had
- 24:28the flu for at least a year, if not more.
- 24:31And it was really a very specialized endeavor.
- 24:35We had to select our patients who we care for, who would benefit the most from treatment,
- 24:40who was likely to complete the treatment, because we didn't want to put people
- 24:44through six months of basically hell in order to only have them quit and not be able to limit.
- 24:51Whereas now we have medications where you can take.
- 24:56One, maybe two or three pills a day for eight to 12 weeks, and be completely cured of hepatitis C.
- 25:05So it's been a huge shift in the paradigm of who ought to be tested and who
- 25:10ought to be treated from very careful patient selection and specialists doing all the work.
- 25:16So we should try to educate people, find your hepatitis C patients and send
- 25:21them to the specialty clinic.
- 25:22Of course, many of them are going to get lost along the way, and not end up getting treatment.
- 25:26So now we've kind of shifted to, if we can find these patients,
- 25:32you can treat them. And it's pretty simple, actually.
- 25:35And I've done podcasts in the past, and there's been quite a few guidelines
- 25:40set up where it can simplify treatment of hepatitis C.
- 25:44So now the whole education is going toward making clinicians realize that it's
- 25:53not really intimidating anymore.
- 25:54You can do it yourself. With the labs that you've already drawn,
- 25:59patients that are in your office at that moment not getting lost by giving a referral.
- 26:06We have trying to get the word out that these new guidelines exist and all you
- 26:13really need is to seek a patient,
- 26:16evaluate whether or not they have some other condition that would make them more complicated.
- 26:22And then for the most part, start them on medication and follow-up is very simple as well.
- 26:28Yeah. And I think what CEI has really tried to empower people.
- 26:33Clinicians, primary care physicians, to really realize that there are so few side effects.
- 26:38There's so much less than even statins that we use so often, you know,
- 26:42and so few tests that you have to get even while people are on these medications
- 26:49that really, you know, Now, in an epidemic, which we have in a hep C epidemic,
- 26:54where you can cure someone, this is really the time to, again,
- 26:57implement this kind of quick test and treat type of thing.
- 27:00And I think what's also very cool is it's curable.
- 27:03There are different things you can cure in medicine. So this is very exciting
- 27:06for both the patient and I think and for the clinician.
- 27:09I almost, the most, the biggest complaint I've seen with patients who are on
- 27:14hepatitis C treatment is, gee, you must have given me the wrong pill because I don't
- 27:20feel it, but it's not making, giving me any side effects.
- 27:23And the second biggest complaint is, aren't you going to test me more and draw
- 27:28blood and all those things?
- 27:29Right. Whereas we really don't have to do very much with that at all. Yeah, no, it's great.
- 27:33And, and I think we can both attest, you know, people with very,
- 27:37you know, people who are very sort of, you know, who may be using drugs or currently
- 27:43homeless, even street homeless. These medications are really good.
- 27:46And even missing a few doses, you know, cure rates are near 100%.
- 27:50And we can get most people through it in cure, which is an extremely exciting
- 27:55thing, not only for the patient's health outcomes, but really for public health
- 27:58in general. The idea of stopping epidemic.
- 28:02Circling back to the syndemics, there are still quite a few challenges.
- 28:06We have this great medicine but we can't roll it out equitably because there are huge,
- 28:11challenges and barriers with that variance and for us
- 28:13who are unhoused and they're just not able to secure and
- 28:16retain their medication and finish that course so you know how do we tie in
- 28:21some of these other services that would really allow us to treat more people
- 28:26effectively for vaccine I think these are sort of the real world question folks
- 28:30are so again it's let's we gotta teach people the science,
- 28:36but we also know that we need to teach people literally the logistics of implementation
- 28:40and the other services that people can use, like peers or care coordinators
- 28:44that can help really successfully get people through these really wonderful
- 28:47biomedical interventions.
- 28:49So I think we've all talked about, really, I mean, these are like kind of extremely
- 28:54innovative science changes that are helping our patients and our communities and our colleagues.
- 28:59And I just wanted to briefly turn over to your, like, a little bit of how we are educating, right?
- 29:04Because I think, you know, old school, you know, we did a lot of in-person education.
- 29:10And that's very, you know, we still do that at conferences. And I think that's
- 29:14extremely helpful, I think. But we also are in a digital world.
- 29:18So I want to turn to Dr. Dye and ask you a little bit about how do we deliver
- 29:23this new innovative science through CEI, through education.
- 29:27So whether it's like virtual platforms or tailored targeted trainings,
- 29:32you know, from your vantage point, what's been key in keeping clinical education
- 29:36both accessible and impactful really in a digital age?
- 29:40You know, where are we now and where can we go as we try to reach more clinicians
- 29:47and health care systems in order really to get this new information out there in a digital age?
- 29:53Well, what's really fascinating is just listening to this conversation for the
- 29:57last half hour, probably 20 to 30 issues have arisen that related to science,
- 30:03the clinical implications of science, equity, policy, implementation.
- 30:07How things are delivered, and how a clinician can know all of that in an atmosphere
- 30:14of constant bombardment with all kinds of information, including a lot of misinformation
- 30:18or poorly designed information. It's impossible.
- 30:21Medical school is not going to do it anymore in terms of preparing you to know
- 30:24all of these things that you really have to be connected to.
- 30:27So the first thing that's required that CEI delivers and other providers do
- 30:33is having a sense of vetted, curated information.
- 30:38So information that's produced by experts, that's vetted and curated,
- 30:42placed where people can access it.
- 30:44So you're not just getting information from just from searching something on
- 30:48the internet without that kind of complicated sort of connections.
- 30:52So just having it vetted and having it curated in one spot is helpful just in and of itself.
- 30:57Another thing that's very important that we have to pay attention to is how
- 31:00people learn. So I never really use the term education in my field. I'm a professor.
- 31:04I just see it as partnering and learning, sharing information, learning skills.
- 31:09And all of that is done in a particular way with adults.
- 31:13I think it's probably done in a particular way with children too,
- 31:16that's not too different from adults, but we act like they're really different.
- 31:19But adults learn because they need to know something. They need to know something
- 31:23in the moment, they have a new,
- 31:25thing that they want to learn. There's a new treatment. That's by getting access
- 31:30to services for their patients.
- 31:31They don't understand why it's going on. So they have a particular thing that they want to know.
- 31:35So how to deliver that information is not by taking a three-credit class on health policy.
- 31:42You need to know in the next five minutes, what chunks of information do you
- 31:47need to know to make this decision or to add to your skills so that you can do that.
- 31:51So part of adult learning is delivering information as you need it,
- 31:56when you need it, how you need it, and what you need.
- 31:59So making sure that that information is delivered in a way that's in chunks.
- 32:04I don't know about you, but when I go to YouTube, I always look for videos that
- 32:07are under five minutes, three minutes.
- 32:09I want to learn something. I just want that. I don't want to hold a lecture on something I want that.
- 32:13So CEI has all kinds of ways of delivering this information,
- 32:17but particularly where you can go into this catalog of information.
- 32:21And find what you're looking for. I think the last thing that's really important
- 32:26that we have to take into account, again, I think this is great for all learners,
- 32:30is telling it to the way you learn.
- 32:32So even at this table, with people sitting around this table,
- 32:35everybody learns differently.
- 32:36Some of us like to be with other people. Some of us want to be online.
- 32:39Some of us are going to be on our phone, in the middle of the night.
- 32:41Some people just want to call, ask questions. So all of those are valid ways
- 32:46of learning and sharing information. and we always have to make sure that we're
- 32:50delivering information that's accessible to all of the learners.
- 32:53But we're going to miss a chunk of learners if you don't do that right.
- 32:56So making sure that we deliver information in as many ways as there are learners,
- 33:01having it be tailored to what people want to know, making sure it's curated,
- 33:06making sure the systems all work so you can log in and get the information and not crash.
- 33:11So all of that has to be paid attention to in this day that we're constantly
- 33:16bombarded with all kinds of information, misinformation, even if you live in
- 33:20a different state other than New York, the information you have access to is already different.
- 33:24So, you know, it's a real jungle in terms of trying to sift through all of this
- 33:29and having a curated spot with
- 33:32accessible information the way you want to learn really helps you learn.
- 33:36Yeah. And I think that's all great.
- 33:39And I think that's what I think is, you know, nice of CEI has sort of different
- 33:43ways in which we do that. Like you said, we have.
- 33:46The online course that you want to, if you want to like have popcorn at midnight
- 33:50and learn something, we have that, but it's a vetted expert that is,
- 33:54you know, from New York state and that's giving you not only the science,
- 33:57but potential implementation and even the policy that goes along with New York
- 34:01state, right? Because policy changes state to state.
- 34:03We have live online courses where you can interact. And I know that your,
- 34:07the research center has really worked hard at making those a lot more interactive, right?
- 34:12Having questions out there, whatever. But we also know that humans like to be
- 34:15in contact, too, and keeping those conferences going where people can kind of
- 34:19come together and chat about both science and limitation and policy are really good.
- 34:24And I think more and more, like you said, you know, doing smaller snippets for
- 34:28people with less time, et cetera, we'll see evolve. I think one of the things
- 34:32you mentioned that I wanted to ask Dr.
- 34:34DiMarco about is calling in real time.
- 34:37I know that the CEI line, actually, particularly for the sexual health,
- 34:42part of our CEI program has been pretty well utilized recently.
- 34:47And I just wanted to let everyone know that actually we have a CEI line that
- 34:50we can call in for sexual health questions, drug user health questions,
- 34:53buprenorphine, hep C, and STIs.
- 34:56And I know given rise and rise of syphilis, we've seen some of that.
- 35:00So I'm just curious about the CEI line and your experience with it.
- 35:03Yeah, I think the CEI line is probably one of the most satisfying pieces of
- 35:08our current program, just because our volume has expanded so much and allowed
- 35:13us to really immediately,
- 35:15sort of real time, respond to the changing epidemic of syphilis and really our local.
- 35:22And regional New York state epidemiology.
- 35:25So with many more cases or many more diagnoses of syphilis and congenital syphilis,
- 35:31we've been able to sort of become that go-to resource for the providers who
- 35:36are just looking to figure out,
- 35:37you know, do I need to do an LP for neurosyphilis?
- 35:40Or, you know, what's the right screening recommendation for these pregnant folks?
- 35:44You know, just when it comes down to syphilis and how do I do that in my practice?
- 35:48Or just something as simple as one of these lab results need.
- 35:52So it's allowed us to really develop relationships with providers across New
- 35:56York, and even relationships with laboratories, hospitals, different types of
- 36:01centers to really improve, that we both improve.
- 36:05through management of pregnant folks with syphilis, the management of neonates with
- 36:10congenital syphilis, but really just looking at syphilis prevention and treatment across New York.
- 36:16And we have for the first time in many years now seen a change in the epidemiology
- 36:23of very few new cases of syphilis in New York State.
- 36:26And though I can't take credit for all of that through CEI, I'd like to think
- 36:30that our provider education initiative,
- 36:34throughout New York has still helped clinicians provide or change the way they
- 36:39provide services when it comes to STIs and systems.
- 36:43Yeah, I think that's really, really amazing. I'm so glad that is available to our New York state clinicians.
- 36:49I also think I just, you know, to sort of wrap up, but I really think it's important,
- 36:53like, as physicians or prescribers in general are listening in,
- 36:58you know, if you're taking care of a pregnant person who may be at risk for
- 37:02syphilis, they may also be, like,
- 37:04also using drugs or have substance use or maybe should be tested for Hep C.
- 37:08I really think the idea is, you know, What is wonderful about CEI is we really
- 37:14are taking a syndemic approach that is really honoring and keeping alive and
- 37:22healthy populations that are often left out of the healthcare system.
- 37:26I think that all of our courses and all of our conferences and a lot of our
- 37:29live interaction stuff can really help take care of not just one patient,
- 37:34one thing for one patient, but perhaps many things for one patient.
- 37:39And all of these trainings are extremely important as we start to realize that
- 37:45primary care is multifaceted.
- 37:48So I thank you all for being here. And thanks for everyone who's listening.
- 37:54Thanks for joining. Thanks for all your expertise and for your help.
- 37:59Thank you for tuning in. Join us next time for a new episode of Conversations
- 38:04with CEI. Visit us at ceitraining.org and follow us on CEI social media platforms.